Peter C Taylor1, Mark C Genovese2, Mike Greenwood3, Meilien Ho3, Evgeny Nasonov4, Barry Oemar5, Rumen Stoilov6, Jiri Vencovsky7, Michael Weinblatt8. 1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 2. Department of Medicine, Stanford University, Stanford, California, USA. 3. AstraZeneca R&D, Macclesfield, UK. 4. Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation. 5. Formerly-AstraZeneca R&D, Boston, Massachusetts, USA. 6. Department of Rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria. 7. Institute of Rheumatology, Charles University, Prague, Czech Republic. 8. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract
OBJECTIVES: OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy versus placebo on the signs and symptoms of rheumatoid arthritis over 6 weeks by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP). METHODS: Overall, 279 patients not currently taking disease-modifying antirheumatic drugs were randomised to: (A) fostamatinib 100 mg twice daily for 24 weeks plus placebo injection every 2 weeks (PBOI); (B) fostamatinib 100 mg twice daily for 4 weeks, then 150 mg once daily up to Week 24, plus PBOI; (C) fostamatinib 100 mg twice daily for 4 weeks, then 100 mg once daily up to Week 24, plus PBOI; (D) adalimumab 40 mg every 2 weeks for 24 weeks, plus oral placebo twice daily; or (E) oral placebo twice daily for 6 weeks, plus PBOI, then a switch to arm A or B. RESULTS: Fostamatinib demonstrated a significant improvement in DAS-28(CRP) score from baseline versus placebo at Week 6 for arms A and B, but not C. Fostamatinib was significantly less effective than adalimumab at Week 24 based on DAS-28(CRP). Adverse events observed with fostamatinib treatment were consistent with those reported in previous studies, including hypertension and diarrhoea. CONCLUSIONS: Fostamatinib demonstrated efficacy as monotherapy, showing superior DAS-28(CRP) score changes between baseline and 6 weeks when compared with placebo in treatment arms A and B. However, all fostamatinib regimens demonstrated inferior responses compared with adalimumab at Week 24. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov: NCT01264770. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
RCT Entities:
OBJECTIVES:OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy versus placebo on the signs and symptoms of rheumatoid arthritis over 6 weeks by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP). METHODS: Overall, 279 patients not currently taking disease-modifying antirheumatic drugs were randomised to: (A) fostamatinib 100 mg twice daily for 24 weeks plus placebo injection every 2 weeks (PBOI); (B) fostamatinib 100 mg twice daily for 4 weeks, then 150 mg once daily up to Week 24, plus PBOI; (C) fostamatinib 100 mg twice daily for 4 weeks, then 100 mg once daily up to Week 24, plus PBOI; (D) adalimumab 40 mg every 2 weeks for 24 weeks, plus oral placebo twice daily; or (E) oral placebo twice daily for 6 weeks, plus PBOI, then a switch to arm A or B. RESULTS:Fostamatinib demonstrated a significant improvement in DAS-28(CRP) score from baseline versus placebo at Week 6 for arms A and B, but not C. Fostamatinib was significantly less effective than adalimumab at Week 24 based on DAS-28(CRP). Adverse events observed with fostamatinib treatment were consistent with those reported in previous studies, including hypertension and diarrhoea. CONCLUSIONS:Fostamatinib demonstrated efficacy as monotherapy, showing superior DAS-28(CRP) score changes between baseline and 6 weeks when compared with placebo in treatment arms A and B. However, all fostamatinib regimens demonstrated inferior responses compared with adalimumab at Week 24. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov: NCT01264770. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Hisashi Yamanaka; Johan Askling; Niklas Berglind; Stefan Franzen; Thomas Frisell; Christopher Garwood; Jeffrey D Greenberg; Meilien Ho; Marie Holmqvist; Laura Novelli Horne; Eisuke Inoue; Kaleb Michaud; Dimitrios A Pappas; George Reed; Deborah Symmons; Eiichi Tanaka; Trung N Tran; Suzanne M M Verstappen; Eveline Wesby-van Swaay; Fredrik Nyberg Journal: RMD Open Date: 2017-10-10
Authors: John C Waterton; Meilien Ho; Lars H Nordenmark; Martin Jenkins; Julie DiCarlo; Gwenael Guillard; Caleb Roberts; Giovanni Buonaccorsi; Geoffrey J M Parker; Michael A Bowes; Charles Peterfy; Herbert Kellner; Peter C Taylor Journal: Eur Radiol Date: 2017-01-23 Impact factor: 5.315
Authors: James Bussel; Donald M Arnold; Elliot Grossbard; Jiří Mayer; Jacek Treliński; Wojciech Homenda; Andrzej Hellmann; Jerzy Windyga; Liliya Sivcheva; Alhossain A Khalafallah; Francesco Zaja; Nichola Cooper; Vadim Markovtsov; Hany Zayed; Anne-Marie Duliege Journal: Am J Hematol Date: 2018-05-15 Impact factor: 10.047